OptiNose (NASDAQ:OPTN) – Equities research analysts at Jefferies Group issued their FY2022 earnings estimates for shares of OptiNose in a research report issued to clients and investors on Thursday, April 5th. Jefferies Group analyst D. Steinberg anticipates that the company will post earnings per share of $2.14 for the year.
A number of other analysts also recently weighed in on the stock. Piper Jaffray set a $28.00 target price on shares of OptiNose and gave the stock a “buy” rating in a research report on Monday, January 15th. Zacks Investment Research downgraded shares of OptiNose from a “hold” rating to a “sell” rating in a research report on Saturday, March 17th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $29.25.
Shares of OptiNose stock opened at $19.30 on Monday. The company has a current ratio of 16.13, a quick ratio of 15.99 and a debt-to-equity ratio of 0.47. The firm has a market cap of $730.81 and a price-to-earnings ratio of -3.43. OptiNose has a 12-month low of $15.01 and a 12-month high of $25.24.
OptiNose (NASDAQ:OPTN) last issued its quarterly earnings data on Tuesday, March 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.18).
In other OptiNose news, CEO Peter K. Miller bought 5,054 shares of OptiNose stock in a transaction dated Friday, March 16th. The shares were purchased at an average cost of $18.58 per share, with a total value of $93,903.32. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Several large investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System purchased a new stake in OptiNose during the 4th quarter valued at about $162,000. TIAA CREF Investment Management LLC purchased a new stake in OptiNose during the 4th quarter valued at about $173,000. Teachers Advisors LLC purchased a new stake in OptiNose during the 4th quarter valued at about $184,000. Millennium Management LLC purchased a new stake in OptiNose during the 4th quarter valued at about $190,000. Finally, Deutsche Bank AG purchased a new stake in OptiNose during the 4th quarter valued at about $247,000. 29.49% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “OptiNose (OPTN) Expected to Post FY2022 Earnings of $2.14 Per Share” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/09/optinose-optn-expected-to-post-fy2022-earnings-of-2-14-per-share.html.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.